EP3453718A4 - Protéine dérivée de bactéries d'acide lactique et son procédé de préparation - Google Patents

Protéine dérivée de bactéries d'acide lactique et son procédé de préparation Download PDF

Info

Publication number
EP3453718A4
EP3453718A4 EP17874171.6A EP17874171A EP3453718A4 EP 3453718 A4 EP3453718 A4 EP 3453718A4 EP 17874171 A EP17874171 A EP 17874171A EP 3453718 A4 EP3453718 A4 EP 3453718A4
Authority
EP
European Patent Office
Prior art keywords
preparation
lactic acid
acid bacteria
protein derived
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17874171.6A
Other languages
German (de)
English (en)
Other versions
EP3453718A1 (fr
EP3453718B1 (fr
Inventor
Myung Jun Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Biotech Co Ltd
Original Assignee
Cell Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Biotech Co Ltd filed Critical Cell Biotech Co Ltd
Publication of EP3453718A1 publication Critical patent/EP3453718A1/fr
Publication of EP3453718A4 publication Critical patent/EP3453718A4/fr
Application granted granted Critical
Publication of EP3453718B1 publication Critical patent/EP3453718B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/41Pediococcus
    • A23V2400/427Pentosaceus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17874171.6A 2016-11-28 2017-02-15 Utilisation de la protéine p8 dérivée des bactéries lactiques comme agent anticancéreux Active EP3453718B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160159479A KR101910808B1 (ko) 2016-11-28 2016-11-28 유산균 유래 p8 단백질 및 이의 항암 용도
PCT/KR2017/001625 WO2018097402A1 (fr) 2016-11-28 2017-02-15 Protéine dérivée de bactéries d'acide lactique et son procédé de préparation

Publications (3)

Publication Number Publication Date
EP3453718A1 EP3453718A1 (fr) 2019-03-13
EP3453718A4 true EP3453718A4 (fr) 2019-12-25
EP3453718B1 EP3453718B1 (fr) 2021-03-31

Family

ID=62195025

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17874171.6A Active EP3453718B1 (fr) 2016-11-28 2017-02-15 Utilisation de la protéine p8 dérivée des bactéries lactiques comme agent anticancéreux

Country Status (7)

Country Link
US (1) US11213565B2 (fr)
EP (1) EP3453718B1 (fr)
JP (1) JP6586248B2 (fr)
KR (1) KR101910808B1 (fr)
CN (1) CN109153706B (fr)
DK (1) DK3453718T3 (fr)
WO (1) WO2018097402A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915951B1 (ko) * 2018-01-09 2018-11-07 주식회사 쎌바이오텍 P8 단백질을 발현 및 분비하는 위장관 질환 치료 약물 전달용 미생물 및 그를 포함하는 위장관 질환 예방 또는 치료용 약제학적 조성물
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
CN110982745B (zh) * 2019-12-24 2021-06-25 扬州大学 一种戊糖片球菌z-1、戊糖片球菌细菌素z-1及戊糖片球菌细菌素z-1的生产方法
KR102719035B1 (ko) * 2020-04-20 2024-10-18 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100232639B1 (ko) 1997-04-15 1999-12-01 김동현 장내 유해효소의 활성을 억제하는 새로운 한국형 유산균 및 그의 용도
WO2009093447A1 (fr) * 2008-01-22 2009-07-30 National University Corporation Asahikawa Medical College Agent antitumoral contre le cancer gastro-intestinal
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
KR101178217B1 (ko) * 2009-10-28 2012-09-07 씨제이제일제당 (주) 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물
KR20110124516A (ko) * 2010-05-11 2011-11-17 포항공과대학교 산학협력단 유산균 배양액 추출물을 포함하는 염증관련질환 치료용 조성물
KR20120015644A (ko) * 2010-08-12 2012-02-22 박진형 항암 활성을 갖는 락토바실러스 균주 및 이를 활성성분으로 포함하는 항암 활성 조성물
KR101427363B1 (ko) 2011-11-23 2014-08-08 주식회사 쎌바이오텍 항암 약제학적 조성물
KR101377617B1 (ko) * 2011-11-23 2014-03-26 주식회사 쎌바이오텍 항알러지 활성을 갖는 피14 단백질 및 이들을 포함하는 항알러지 약제학적 조성물
WO2013077534A1 (fr) * 2011-11-23 2013-05-30 Cell Biotech Co., Ltd. Protéine p14 ayant une activité anti-cancéreuse et antiallergique et composition pharmaceutique comprenant celle-ci
WO2014096901A1 (fr) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Souche de bifidobacterium animalis ssp. animalis
EP3033091B1 (fr) * 2013-08-16 2022-09-07 Versitech Limited Composition probiotique et utilisation de celle-ci dans la prevention et le traitement du carcinome hepatocellulaire
KR101656208B1 (ko) 2014-11-04 2016-09-12 주식회사 쎌바이오텍 염증 질환 예방 또는 치료용 조성물
CN104388503B (zh) * 2014-11-24 2017-05-03 天津商业大学 一种乳酸菌胞外蛋白的提取方法及应用
KR101743043B1 (ko) 2016-06-28 2017-06-02 바이오제닉스코리아 주식회사 장내환경개선효과를 갖는 나노형 김치 유산균 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABDUL ARIF KHAN ET AL: "Gut Microbiota and Probiotics: Current Status and Their Role in Cancer Therapeutics", DRUG DEVELOPMENT RESEARCH., vol. 74, no. 6, 3 July 2013 (2013-07-03), US, pages 365 - 375, XP055289994, ISSN: 0272-4391, DOI: 10.1002/ddr.21087 *
JUANITA ESCAMILLA ET AL: "Cell-Free Supernatants from Probiotic Lactobacillus casei and Lactobacillus rhamnosus GG Decrease Colon Cancer Cell Invasion In Vitro", NUTRITION AND CANCER, vol. 64, no. 6, 1 August 2012 (2012-08-01), US, pages 871 - 878, XP055641523, ISSN: 0163-5581, DOI: 10.1080/01635581.2012.700758 *
KIM ET AL: "Cancer chemopreventive effects of lactic acid bacteria", JOURNAL OF THE ALL-INDIA OPHTHALMOLOGICAL SOCIETY, MEDKNOW PUBLICATIONS AND MEDIA PVT. LTD, INDIA, vol. 17, no. 8, 1 January 2007 (2007-01-01), pages 1227 - 1235, XP008160403, ISSN: 0044-7307 *
LI ZHONG ET AL: "Emerging roles of lactic acid bacteria in protection against colorectal cancer", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 20, no. 24, 1 January 2014 (2014-01-01), CN, pages 7878 - 7886, XP055531727, ISSN: 1007-9327, DOI: 10.3748/wjg.v20.i24.7878 *
UNIPROT DB: "UPI00019F7D40", UNIPROT, 16 June 2009 (2009-06-16), XP055641481, Retrieved from the Internet <URL:https://www.uniprot.org/uniparc/UPI00019F7D40> [retrieved on 20191112] *

Also Published As

Publication number Publication date
US11213565B2 (en) 2022-01-04
US20190201481A1 (en) 2019-07-04
JP2019521089A (ja) 2019-07-25
JP6586248B2 (ja) 2019-10-02
KR101910808B1 (ko) 2018-10-24
EP3453718A1 (fr) 2019-03-13
WO2018097402A1 (fr) 2018-05-31
DK3453718T3 (da) 2021-04-19
CN109153706A (zh) 2019-01-04
CN109153706B (zh) 2022-01-21
EP3453718B1 (fr) 2021-03-31
KR20180060228A (ko) 2018-06-07

Similar Documents

Publication Publication Date Title
EP3495362A4 (fr) Dérivé de l&#39;acide thioglycolique imidazopyridine, son procédé de préparation et son application
EP3614928A4 (fr) Système d&#39;imagerie tissulaire et procédé d&#39;imagerie tissulaire
EP3497428C0 (fr) Systèmes et procédés de préparation automatisée d&#39;échantillons biologiques
EP3615135A4 (fr) Système d&#39;implant rachidien et procédé associé
ME03487B (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l&#39;hypersensibilité viscérale
EP3550960A4 (fr) Système et procédés de lutte biologique contre des pathogènes des plantes
EP3525700A4 (fr) Système et procédé d&#39;implant rachidien
EP3342554A4 (fr) Système robotique et son procédé d&#39;actionnement
EP3544662A4 (fr) Tuyaux médicaux et procédés de fabrication
EP3398939A4 (fr) Dérivé d&#39;acrylanilide, son procédé de préparation et ses applications en pharmacie
EP3294108A4 (fr) Procédé et système de stérilisation à la vapeur d&#39;endoscopes
EP3554521A4 (fr) Composition orale contenant des bactéries d&#39;acide lactique pour réguler des réactions immunitaires et méthodes associées
EP3437637A4 (fr) Préparation pharmaceutique de palbociclib et son procédé de préparation
EP3419563A4 (fr) Système d&#39;implant rachidien et procédé
EP3732461C0 (fr) Procédé et système de préparation d&#39;un échantillon de tissu biologique
FR3019004B1 (fr) Aliment comprenant des proteines essentiellement d&#39;origine vegetale et son procede de preparation
EP3389571A4 (fr) Système et procédé d&#39;implant rachidien
EP3632326A4 (fr) Système et procédé d&#39;imagerie médicale
EP3476871A4 (fr) Polymère d&#39;oléfine et procédé de préparation associé
EP3395227A4 (fr) Système d&#39;endoscope et procédé de fonctionnement de système d&#39;endoscope
EP3470389A4 (fr) Appareil et procédé de préparation d&#39;acide formique
EP3520670A4 (fr) Système d&#39;endoscope et son procédé de fonctionnement
EP3777544C0 (fr) Procédés pour fabriquer des produits laitiers de culture longue conservation
EP3236759C0 (fr) Concentre de proteines de lactoserum, produits laitiers fermentes comprenant le concentre et methodes de preparation
EP3453718A4 (fr) Protéine dérivée de bactéries d&#39;acide lactique et son procédé de préparation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELL BIOTECH CO., LTD.

Owner name: CHUNG, MYUNG JUN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELL BIOTECH CO., LTD.

A4 Supplementary search report drawn up and despatched

Effective date: 20191121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/747 20150101ALI20191115BHEP

Ipc: A23L 33/18 20160101ALI20191115BHEP

Ipc: A61K 38/16 20060101ALI20191115BHEP

Ipc: A61K 35/744 20150101ALI20191115BHEP

Ipc: C07K 14/335 20060101AFI20191115BHEP

Ipc: C12N 15/74 20060101ALI20191115BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHUNG, MYUNG JUN

INTG Intention to grant announced

Effective date: 20200806

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20201028

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1376837

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210414

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017035940

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TR-IP CONSULTING LLC, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210630

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210331

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1376837

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210731

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210802

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017035940

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20170215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250301

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

REG Reference to a national code

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251223

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260219

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260223

Year of fee payment: 10

Ref country code: DK

Payment date: 20260217

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20260218

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260219

Year of fee payment: 10